

Joshua D Grill

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4414259/publications.pdf>

Version: 2024-02-01

66
papers

1,717
citations

279798

23
h-index

302126

39
g-index

66
all docs

66
docs citations

66
times ranked

2036
citing authors

#	ARTICLE	IF	CITATIONS
1	Diversifying Recruitment Registries: Considering Neighborhood Health Metrics. <i>Journal of Prevention of Alzheimer's Disease</i> , 2022, 9, 1-7.	2.7	0
2	Online seminars as an information source for direct-to-consumer stem cell therapy. <i>Regenerative Medicine</i> , 2022, 17, 81-90.	1.7	5
3	Moving beyond disclosure: Stages of care in preclinical Alzheimer's disease biomarker testing. <i>Alzheimer's and Dementia</i> , 2022, 18, 1969-1979.	0.8	8
4	Alzheimer's Disease Clinical Trial Study Partners. , 2022, , 333-342.		0
5	You've Got a Friend in Me: How Cognitively Unimpaired Older Adults Select a Study Partner to Participate with Them in Alzheimer's Disease Research. <i>Journal of Alzheimer's Disease</i> , 2022, , 1-13.	2.6	2
6	Retaining Participants in Longitudinal Studies of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2022, 87, 945-955.	2.6	4
7	Strategies Associated with Retaining Participants in the Longitudinal National Alzheimer's Coordinating Center Uniform Data Set Study. <i>Journal of Alzheimer's Disease</i> , 2022, 87, 1557-1566.	2.6	2
8	Dyadic Enrollment in a Phase 3 Mild Cognitive Impairment Clinical Trial. <i>Alzheimer Disease and Associated Disorders</i> , 2022, Publish Ahead of Print, .	1.3	2
9	Direct Mail Recruitment to a Potential Participant Registry. <i>Alzheimer Disease and Associated Disorders</i> , 2021, 35, 80-83.	1.3	4
10	Asian Americans and Pacific Islanders' perspectives on participating in the CARE recruitment research registry for Alzheimer's disease and related dementias, aging, and caregiving research. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021, 7, e12195.	3.7	5
11	Recruitment and retention of participant and study partner dyads in two multinational Alzheimer's disease registration trials. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 16.	6.2	11
12	Research Attitudes Questionnaire scores predict Alzheimer's disease clinical trial dropout. <i>Clinical Trials</i> , 2021, 18, 237-244.	1.6	9
13	Implications of FDA Approval of a First Disease-Modifying Therapy for a Neurodegenerative Disease on the Design of Subsequent Clinical Trials. <i>Neurology</i> , 2021, 97, 496-500.	1.1	5
14	The approval of Aduhelm risks eroding public trust in Alzheimer research and the FDA. <i>Nature Reviews Neurology</i> , 2021, 17, 523-524.	10.1	44
15	Disparities by Race and Ethnicity Among Adults Recruited for a Preclinical Alzheimer Disease Trial. <i>JAMA Network Open</i> , 2021, 4, e2114364.	5.9	68
16	Reasons for undergoing amyloid imaging among cognitively unimpaired older adults. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1646-1655.	3.7	5
17	On the design of early-phase Alzheimer's disease clinical trials with cerebrospinal fluid tau outcomes. <i>Clinical Trials</i> , 2021, 18, 714-723.	1.6	3
18	A Scoping Review of Dietary Factors Conferring Risk or Protection for Cognitive Decline in APOE ϵ 4 Carriers. <i>Journal of Nutrition, Health and Aging</i> , 2021, 25, 1167-1178.	3.3	1

#	ARTICLE	IF	CITATIONS
19	Short-term Psychological Outcomes of Disclosing Amyloid Imaging Results to Research Participants Who Do Not Have Cognitive Impairment. <i>JAMA Neurology</i> , 2020, 77, 1504.	9.0	48
20	Racial and ethnic differences in older adults' willingness to be contacted about Alzheimer's disease research participation. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12023.	3.7	25
21	Participant and study partner prediction and identification of cognitive impairment in preclinical Alzheimer's disease: study partner vs. participant accuracy. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 85.	6.2	13
22	Response to "Avoiding Methodological Bias in Studies of Amyloid Imaging Results Disclosure". <i>Alzheimer's Research and Therapy</i> , 2019, 11, 51.	6.2	0
23	Retention of Alzheimer Disease Research Participants. <i>Alzheimer Disease and Associated Disorders</i> , 2019, 33, 299-306.	1.3	24
24	Study partner types and prediction of cognitive performance: implications to preclinical Alzheimer's disease trials. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 92.	6.2	13
25	Recruiting the Oldest-old for Clinical Research. <i>Alzheimer Disease and Associated Disorders</i> , 2019, 33, 160-162.	1.3	11
26	Which MCI Patients Should be Included in Prodromal Alzheimer Disease Clinical Trials?. <i>Alzheimer Disease and Associated Disorders</i> , 2019, 33, 104-112.	1.3	12
27	A Preliminary Study of Clinical Trial Enrollment Decisions Among People With Mild Cognitive Impairment and Their Study Partners. <i>American Journal of Geriatric Psychiatry</i> , 2019, 27, 322-332.	1.2	20
28	Reactions to learning a "not elevated" amyloid PET result in a preclinical Alzheimer's disease trial. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 125.	6.2	20
29	Public Understanding and Opinions regarding Genetic Research on Alzheimer's Disease. <i>Public Health Genomics</i> , 2018, 21, 228-237.	1.0	5
30	Constructing a Local Potential Participant Registry to Improve Alzheimer's Disease Clinical Research Recruitment. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 1055-1063.	2.6	37
31	Study partners: essential collaborators in discovering treatments for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 101.	6.2	29
32	Changes in regional cerebral blood flow associated with a 45-day course of the ketogenic agent, caprylidene, in patients with mild to moderate Alzheimer's disease: Results of a randomized, double-blinded, pilot study. <i>Experimental Gerontology</i> , 2018, 111, 118-121.	2.8	45
33	African Americans are less likely to enroll in preclinical Alzheimer's disease clinical trials. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 57-64.	3.7	71
34	Recruiting to preclinical Alzheimer's disease clinical trials through registries. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 205-212.	3.7	17
35	Patient and caregiver reactions to clinical amyloid imaging. <i>Alzheimer's and Dementia</i> , 2017, 13, 924-932.	0.8	30
36	Attitudes toward Potential Participant Registries. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 939-946.	2.6	9

#	ARTICLE	IF	CITATIONS
37	Communicating mild cognitive impairment diagnoses with and without amyloid imaging. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 35.	6.2	46
38	Participantâ€“Informant Relationships Affect Quality of Life Ratings in Incipient and Clinical Alzheimer Disease. <i>American Journal of Geriatric Psychiatry</i> , 2017, 25, 297-307.	1.2	10
39	Attitudes toward clinical trials across the Alzheimerâ€™s disease spectrum. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 81.	6.2	33
40	Study partners should be required in preclinical Alzheimerâ€™s disease trials. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 93.	6.2	22
41	Critical review of the Appropriate Use Criteria for amyloid imaging: Effect on diagnosis and patient care. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 5, 15-22.	2.4	29
42	P3â€“006: Racial Differences in Willingness to Enroll in Preclinical Alzheimer's Disease Clinical Trials. <i>Alzheimer's and Dementia</i> , 2016, 12, P819.	0.8	0
43	P4â€“328: Communicating Mild Cognitive Impairment Diagnosis with and Without Amyloid Imaging: Recommendations From An Expert Workgroup. <i>Alzheimer's and Dementia</i> , 2016, 12, P1160.	0.8	0
44	Disclosure of amyloid status is not a barrier to recruitment in preclinical Alzheimer's disease clinical trials. <i>Neurobiology of Aging</i> , 2016, 39, 147-153.	3.1	35
45	S3-02-04: Ethics in Alzheimer's disease prevention clinical trial design. , 2015, 11, P211-P211.		0
46	A survey of attitudes toward clinical trials and genetic disclosure in autosomal dominant Alzheimerâ€™s disease. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 50.	6.2	10
47	Frequency and Impact of Informant Replacement in Alzheimer Disease Research. <i>Alzheimer Disease and Associated Disorders</i> , 2015, 29, 242-248.	1.3	10
48	Consider the Source. <i>Alzheimer Disease and Associated Disorders</i> , 2015, 29, 364.	1.3	2
49	Does Alzheimer Disease Pathologic Change Underlie Subjective Cognitive Complaints?. <i>Alzheimer Disease and Associated Disorders</i> , 2015, 29, 350-352.	1.3	5
50	Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 26.	6.2	106
51	Why are Spousal Caregivers More Prevalent than Nonspousal Caregivers as Study Partners in AD Dementia Clinical Trials?. <i>Alzheimer Disease and Associated Disorders</i> , 2015, 29, 70-74.	1.3	35
52	Targeting Prodromal Alzheimer Disease With Avagacestat. <i>JAMA Neurology</i> , 2015, 72, 1324.	9.0	179
53	Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimerâ€™s disease clinical trials. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 39.	6.2	19
54	Facilitating Alzheimer Disease Research Recruitment. <i>Alzheimer Disease and Associated Disorders</i> , 2014, 28, 1-8.	1.3	86

#	ARTICLE	IF	CITATIONS
55	Choosing Alzheimer's disease prevention clinical trial populations. <i>Neurobiology of Aging</i> , 2014, 35, 466-471.	3.1	15
56	Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging Initiative. <i>Neurobiology of Aging</i> , 2013, 34, 62-72.	3.1	49
57	The impact of the availability of prevention studies on the desire to undergo predictive testing in persons at risk for autosomal dominant Alzheimer's disease. <i>Contemporary Clinical Trials</i> , 2013, 36, 256-262.	1.8	18
58	Risk disclosure and preclinical Alzheimer's disease clinical trial enrollment. <i>Alzheimer's and Dementia</i> , 2013, 9, 356.	0.8	33
59	Should we disclose amyloid imaging results to cognitively normal individuals?. <i>Neurodegenerative Disease Management</i> , 2013, 3, 43-51.	2.2	29
60	Effect of study partner on the conduct of Alzheimer disease clinical trials. <i>Neurology</i> , 2013, 80, 282-288.	1.1	58
61	Does Study Partner Type Impact the Rate of Alzheimer's Disease Progression?. <i>Journal of Alzheimer's Disease</i> , 2013, 38, 507-514.	2.6	4
62	Are Patients Whose Study Partners Are Spouses More Likely to be Eligible for Alzheimer's Disease Clinical Trials. <i>Dementia and Geriatric Cognitive Disorders</i> , 2012, 33, 334-340.	1.5	25
63	Should persons with autosomal dominant AD be included in clinical trials?. <i>Alzheimer's Research and Therapy</i> , 2011, 3, 18.	6.2	2
64	Current therapeutic targets for the treatment of Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2010, 10, 711-728.	2.8	101
65	Addressing the challenges to successful recruitment and retention in Alzheimer's disease clinical trials. <i>Alzheimer's Research and Therapy</i> , 2010, 2, 34.	6.2	144
66	Perceptions of Research Burden and Retention Among Participants in ADRC Cohorts. <i>Alzheimer Disease and Associated Disorders</i> , 0, Publish Ahead of Print, .	1.3	5